SHP2 inhibitors Archives

BMS & BridgeBio team up in nearly $1B oncology pact

Biopharma Companies, BioSpace, Bristol Myers Squibb, Business, Cancer, Collaborations, Commercialization, Deals, Licensing, MD Anderson Cancer Center, Oncology, R&D, R&D, SHP2 inhibitors, Tumors

BridgeBio announced that the Palo Alto, Calif.-based biopharmaceutical company signed an exclusive deal with Bristol Myers Squibb to develop and commercialize a potential treatment for cancer.

Mirati and Sanofi Unite on Trial for KRAS Inhibitor

Agreements, Business, Clinical Trials, Colorectal Cancer, Deals, G12C KRAS inhibitors, KRAS G12C Mutations, Non-Small Cell Lung Cancer, R&D, Sanofi, SHP2 inhibitors

Fresh off a presentation of positive data showing that the KRASG12C inhibitor adagrasib benefited colorectal and lung cancer patients, Mirati Therapeutics forged an agreement to combine the drug with Sanofi’s company’s SHP2 inhibitor SAR442720 in lung cancer.

BridgeBio & Bristol Myers Squibb partner for KRAS combination therapy in solid tumor cancers

Bristol Myers Squibb, Business, Checkpoint Inhibitors, Clinical Trials, Collaborations, Combination Therapies, KRAS Mutations, R&D, SHP2 inhibitors, Solid Tumors

California-based biopharmaceutical firm BridgeBio Pharma announced a funding collaboration with Bristol Myers Squibb to evaluate a potential treatment for patients with difficult-to-treat cancers.